

Pharnext Announces the Appointment of René Goedkoop as Chief Medical Officer and François Chamoun as General Counsel

Paris, July 26, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced that it has appointed René Goedkoop, M.D. as Chief Medical Officer and François Chamoun as General Counsel. Both Dr. Goedkoop and Mr. Chamoun bring highly valuable expertise in clinical development and legal affairs.

- **René Goedkoop, Chief Medical Officer**, has over 25 years of experience in worldwide clinical product development with emphasis on “first-in-class” therapeutic solutions for inflammatory diseases including rare CNS disorders, cancer and cardiovascular diseases. He worked in start-up and large biopharmaceutical companies such as Centocor, Eli Lilly, Serono, Modex or Apoxis, and directly interacted with key regulatory agencies (FDA, EMA, Korea, Japan and China). As an independent consultant, he conducted due diligences and helped develop business plans for *de novo* biotech companies for venture capital investors. Dr. Goedkoop received his M.D. at the University of Amsterdam followed by a residency in cardiopulmonary surgery.
- **François Chamoun, General Counsel**, has more than 15 years of legal affairs experience, covering the full value chain within private healthcare companies. Before joining Pharnext, Mr. Chamoun, as Head of Legal Affairs for a family office, participated in launching and securing funding for Steba Biotech, a biotechnology group in oncology. Previously, as Head of Legal Affairs, he participated in capitalistic restructuring activities for a holding company that owned the pharmaceutical company Laboratoires Negma-Lerads. He also managed legal affairs for Talento Ventures, a seed-capital fund, dedicated to new and innovative technologies. Mr. Chamoun holds a Masters Degree in business law and a D.J.C.E. from the University of Toulouse.

“I am delighted to welcome Dr. René Goedkoop as Chief Medical Officer and Mr. François Chamoun as General Counsel to Pharnext,” said **Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext.** *“Dr. Goedkoop’s deep expertise in clinical development strategy and implementation will be instrumental for us as we pursue the development of PXT3003, currently in Phase 3 for Charcot-Marie-Tooth disease type 1A, and also for PXT864 in Alzheimer’s disease and other neurological indications. Additionally, as Pharnext continues its growth following its recent IPO, the legal expertise of Mr. Chamoun in the healthcare sector will be critical. These two new executives will strengthen the management team and surely help us to reach our ultimate goal: give patients suffering from severe diseases with no valuable therapeutic alternatives access to more efficacious, safer and affordable treatments.”*

CONTACTS:

Pharnext	NewCap	Media Relations (Europe)	Media Relations (US)
Daniel Cohen, M.D., Ph.D. Chief Executive Officer contact@pharnext.com +33 (0)1 41 09 22 30	Investors Relations Julie Coulot pharnext@newcap.eu +33 (0)1 44 71 20 40	Alize RP Caroline Carmagnol Margaux Pronost pharnext@alizerp.com +33 (0)1 44 54 36 64	Russo Partners Tony Russo, Ph.D. Matt Middleman, M.D. tony.russo@russopartnersllc.com matt.middleman@russopartnersllc.com +1 212-845-4251 +1 212-845-4272

About Pharnext

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: pleotherapy. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These "pleodrugs" offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, please visit www.pharnext.com